Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
June 2014 Volume 10, Issue 6
http://www.landesbioscience.com/journals/vaccines/toc/volume/10/issue/6/

Short Report
HPV vaccine uptake after introduction of the vaccine in Germany: An analysis of administrative data
Sabrina Hense, Kathrin Hillebrand, Johannes Horn, Rafael Mikolajczyk, Renate Schulze-Rath and Edeltraut Garbe
http://dx.doi.org/10.4161/hv.28450
Abstract
In Germany, vaccination against human papilloma virus (HPV) is recommended by the German Standing Vaccination Committee (STIKO) since March 2007 for girls aged 12–17 years. The vaccine is free of charge for this age group. Additionally, some statutory health insurance providers (SHI) offer reimbursement for women aged 18–26 years. Currently available information on the uptake or coverage of HPV vaccination is limited to specific regions, age groups, or study populations.
This report describes the HPV vaccine uptake in 2008 for females aged 12–26 years in Germany on a broad regional level based on data from one large SHI. HPV vaccinations were identified by outpatient codes used for reimbursement of vaccine administration. Vaccine uptake was calculated by dividing the number of females, who received at least one HPV vaccine dose by the number of female insurees in the respective age group. The overall study population consisted of 317,234 females, of whom 77,350 received at least one HPV vaccine dose in 2008. Vaccine uptake was 32.2% in the recommended age group, with a peak age at 14–16 years. In the age group of females aged 18–26 years, where HPV vaccination was not officially recommended by the STIKO, uptake was 12.3%. Vaccine uptake in 2008 reflects an early stage after the recommendation of HPV vaccination in 2007. Future changes in vaccine uptake should be further and more promptly monitored.